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Aims Proprotein convertase subtilisin/kexin type-9 (PCSK9), a molecular determinant of low-density lipoprotein (LDL) recep-
tor (LDLR) fate, has emerged as a promising therapeutic target for atherosclerotic cardiovascular diseases. However,
the precise mechanism by which PCSK9 regulates the internalization and lysosomal degradation of LDLR is unknown.
Recently, we identified adenylyl cyclase-associated protein 1 (CAP1) as a receptor for human resistin whose globular
C-terminus is structurally similar to the C-terminal cysteine-rich domain (CRD) of PCSK9. Herein, we investigated the




The direct binding between PCSK9 and CAP1 was confirmed by immunoprecipitation assay, far-western blot, bio-
molecular fluorescence complementation, and surface plasmon resonance assay. Fine mapping revealed that the
CRD of PCSK9 binds with the Src homology 3 binding domain (SH3BD) of CAP1. Two loss-of-function polymor-
phisms found in human PCSK9 (S668R and G670E in CRD) were attributed to a defective interaction with CAP1.
siRNA against CAP1 reduced the PCSK9-mediated degradation of LDLR in vitro. We generated CAP1 knock-out
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mice and found that the viable heterozygous CAP1 knock-out mice had higher protein levels of LDLR and
lower LDL-C levels in the liver and plasma, respectively, than the control mice. Mechanistic analysis revealed that
PCSK9-induced endocytosis and lysosomal degradation of LDLR were mediated by caveolin but not by clathrin,
and they were dependent on binding between CAP1 and caveolin-1.
...................................................................................................................................................................................................
Conclusion We identified CAP1 as a new binding partner of PCSK9 and a key mediator of caveolae-dependent endocytosis
and lysosomal degradation of LDLR.
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Introduction
Proprotein convertase subtilisin/kexin type-9 (PCSK9) determines
plasma low-density lipoprotein (LDL) cholesterol (LDL-C) levels by
regulating internalization and lysosomal degradation of the LDL recep-
tor (LDLR)1 and has emerged as a promising therapeutic target.2
Inhibitors of PCSK9 have reduced plasma LDL-C levels and improved
cardiovascular outcomes.3,4 However, the precise mechanism by
which PCSK9 determines the fate of LDLR has not been elucidated.
The LDLR enters cells while bound to LDL-C, dissociates from LDL-
C in endosomes, and is recycled to the cell surface, whereas LDL-C is
directed to lysosomes for degradation. In contrast, if bound to PCSK9,
LDLR is internalized and escorted to lysosomes for degradation
through an unknown mechanism.1 Although PCSK9 is a proteinase K-
like serine protease, after autocatalytic cleavage, the terminal portion
of the pro-domain (amino acids 32-152) covers the catalytic triad, pre-
venting further proteolytic activity.1,2 The catalytic domain of PCSK9
binds LDLR, and another part of PCSK9, i.e. the C-terminal cysteine-
rich domain (CRD), is suspected to interact with a putative
membrane-bound protein that escorts the protein complex towards
lysosomal degradation.1 Recently, PCSK9-CRD has been reported to
have structural homology with the human resistin C-terminal domain
homotrimer,5 which is a pro-inflammatory cytokine inducing athe-
rosclerosis.6 In our previous paper, we firstly reported that adenylyl
cyclase-associated protein 1 (CAP1), which is a conserved protein
known as a component of Saccharomyces cerevisiae adenylyl cyclase
complex,7 is a surface receptor that binds the C-terminal domain of
homo-trimer human resistin.8 Thus, we think that CAP1 binds to
resistin as well as CRD of PCSK9. Furthermore, CAP1 is known to
regulate actin filament dynamics important for cell morphology, migra-
tion, and endocytosis.9 Therefore, we hypothesized that CAP1 is the
unknown protein that interacts with PCSK9-CRD to escort the
LDLR-PCSK9 complex towards lysosomal degradation.
Materials and methods
All animal studies were approved by the Institutional Animal Care
and Use Committee (IACUC) of the Clinical Research Institute in
Seoul National University Hospital, Korea. For a detailed description
of all methods, see the Supplementary material online, Experimental
Procedures.
Results
CRD of PCSK9 directly binds CAP1
A physical interaction between CAP1 and PCSK9 was shown in
mouse liver tissue using immunoprecipitation (Figure 1A). For far-
western blot analysis,10 purified mFc-CAP1 or His-PCSK9 was used
as prey under the non-reducing condition and probed with His-
PCSK9 or mFc-CAP1 as bait, respectively (Figure 1B). To visualize this
interaction in living cells, we performed a bimolecular fluorescent
complementation assay based on the complementation between
two non-fluorescent fragments of fluorescent protein that are
brought together by an interaction between proteins fused to each
fragment,11 which clearly visualized the direct binding between
hCAP1 and hPCSK9 in living cells (Figure 1C). In addition, the im-
munofluorescent staining of HepG2 cells exogenously treated with
recombinant PCSK9 demonstrated that PCSK9 was colocalized with
CAP1 and LDLR in the membrane and cytosol (Figure 1D). Finally, a
direct binding assay using a surface plasmon resonance-based system
yielded an increase of response units between PCSK9 and CAP1 in a
dose-dependent manner (Figure 1E).
Since we previously identified that the Src homology 3 binding do-
main (SH3BD) of CAP1 is a binding partner of the C-terminal domain
of homo-trimer human resistin, which has structural homology with
the CRD of PCSK9,8 we tested whether the SH3BD of CAP1 binds
Translational perspective
Although monoclonal antibodies to proprotein convertase subtilisin/kexin type-9 (PCSK9) have been approved to lower plasma low-density
lipoprotein (LDL) cholesterol levels and improve clinical outcomes in patients with atherosclerotic cardiovascular diseases, the precise mech-
anism of how PCSK9 directs LDL receptor (LDLR) to lysosomal degradation is unclear. We have disputed the previous notion that LDLR deg-
radation is mediated by clathrin. We identified adenylyl cyclase-associated protein 1 as a liaison between the PCSK9-LDLR complex and
caveolin, which directs the complex to caveolae-mediated endocytosis and lysosomal degradation. Our findings will change LDLR degradation
biology from a PCSK9-centric view to a broader and more balanced view, contributing to the emergence of another new therapeutic strategy
for dyslipidaemia and atherosclerotic cardiovascular diseases.
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Figure 1 CAP1 directly interacts with PCSK9. (A) Immunoprecipitation of endogenous CAP1 or PCSK9 from liver lysates of C57/BL6 wild-type
mice. (B) Far-western blot analysis of mFc-hCAP1 and hPCSK9-His. (C) Bimolecular fluorescence complementation assay visualizing the interaction
between hCAP1 and hPCSK9 in living cells. Green fluorescence was observed when CAP1 and PCSK9 fused to each fragment (pVC155 and
pVN173) and were both expressed (left panel). However, when human CAP1 or PCSK9 was expressed alone, no fluorescence was detected (middle
and right panel, respectively). (D) Colocalization of CAP1 and PCSK9 as determined by immunofluorescent staining of HepG2 cells exogenously
treated with recombinant hPCSK9. Overlap coefficients: mean ± standard deviation.
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Figure 1 Continued.
(E) Direct binding assay between rhPCSK9 and CAP1 using surface plasmon resonance. The equilibrium dissociation constant was 1.01 mM. (F)
Coimmunoprecipitation of hPCSK9-Flag and wild-type CAP1 or each CAP1 mutant in HEK 293 cells. Pro-PCSK9 (P) and mature PCSK9 (M) are indi-
cated with bold line. (G) Coimmunoprecipitation of hPCSK9-Flag and the SH3BD of CAP1 in HEK 293 cells showing that the SH3BD is sufficient for
binding to CAP1. (H) Coimmunoprecipitation of wild-type hCAP1 with wild-type PCSK9 or the CRD deletion PCSK9 mutant in HEK 293 cells show-
ing that PCSK9 binds CAP1 via the CRD.
























the CRD of PCSK9. We carried out an in vitro coimmunoprecipitation
assay with wtPCSK9-Flag and the following CAP1 mutants: an adenylyl
cyclase-binding domain deletion mutant (~ACBD mutant), an actin
binding deletion mutant (~ActinBD mutant), and a mutant with a de-
letion of both the SH3BD and ActinBD (~SH3BD ~ActinBD mu-
tant). PCSK9 interacted with wtCAP1, the ~ACBD mutant, and the
~ActinBD mutant but not with the ~SH3BD~ ActinBD mutant,
suggesting that CAP1 binds PCSK9 via the SH3BD (Figure 1F). The
SH3BD of CAP1 is sufficient for interacting with PCSK9 (Figure 1G).
CAP1 bound wtPCSK9 but not the CRD deletion mutant (Figure 1H).
A 3D molecular modelling analysis of the complex using a protein–pro-
tein docking simulation and a binding energy score analysis determined
the key binding interactions among Asp34B in the SH3BD of CAP and
Lys494 in the M1 domain and Arg659 in the M3 domain of PCSK9-
CRD (Supplementary material online, Figure S1).
PCSK9 loss-of-function mutants (S668R
and G670E in CRD) cannot interact with
CAP1
We generated eight PCSK9 point mutants by site-directed mutagen-
esis of PCSK9-CRD, covering the well-known loss-of-function and
gain-of-function variations found in human genetic studies (Figure 2A).
Q544E and H683fs mutants of PCSK9 were not expressed in the
HepG2 cells, suggesting that these mutants are related to protein ex-
pression or stability. S668R and G670E mutants in the CRD of
PCSK9 were well expressed, but their binding to CAP1 was severely
compromised as assessed by immunoprecipitation (Figure 2B), sug-
gesting that the CRD of PCSK9 is important for binding to CAP1 and
for regulating LDLR protein (and, thus, LDL-C levels in humans). To
further characterize the direct interaction of PCSK9-CRD mutation
Figure 2 Human PCSK9 loss-of-function mutants have weaker interactions with CAP1 than the wild type. (A) The single-nucleotide variants of
PCSK9-CRD reported to be associated with plasma LDL cholesterol levels in humans. (B) The loss-of-function PCSK9 mutants S668R and G679E
lose their binding affinity to CAP1. CAP1-Myc and either wild-type PCSK9-Flag or each point mutant of PCSK9-Flag were overexpressed in HEK293
cells. Immunoprecipitation with Flag and immunoblotting with Myc (upper two figures of immunoblot), or immunoprecipitation with Myc and im-
munoblotting with Flag (immunoblot on the third and fourth lines). The level of PCSK9 in the culture media (the lowest line).
























































































with CAP1, we measured the binding affinity of PCSK9 WT, PCSK9
A514T, PCSK9 G670E, and PCSK9 S668RG670E against CAP1
(Supplementary material online, Figure S2, equilibrium dissociation
constant, kD: 0.45mM, 0.11mM, 0.96mM, and 2.32mM, respectively).
PCSK9 A514T showed a stronger interaction relative to WT, where-
as G670E and G670ES668R mutants showed weak interactions.
CAP1 induces PCSK9-mediated LDLR
degradation and increases the LDL-C
level
PCSK9 treatment dose-dependently promoted LDLR degradation in
HepG2 cells12 (Supplementary material online, Figure S3). Once
CAP1 was depleted with siRNA (siCAP1), LDLR degradation by ex-
ogenous PCSK9 was significantly attenuated (Figure 3A). In addition,
Supplementary material online, Figure S4 demonstrated that LDLR
and exogenous His-tagged PCSK9 were less detectable in the cytosol
of the CAP1 siRNA-treated cells both 30 and 60 min after His-
rhPCSK9 treatment. We rescued the CAP1 deficient cells (siCAP1)
with wtCAP1 or each of the CAP1 mutants by overexpression and
examined the PCSK9-mediated LDLR degradation. In Figure 3B, only
wtCAP1 and the ~actinBD mutant rescued the attenuated PCSK9-
mediated LDLR degradation, which suggests that the SH3BD and
ACBD are critical for exogenous PCSK9-mediated LDLR degrad-
ation. To examine whether CAP1 regulates PCSK9 interaction with
the EGF-A domain of LDLR, we performed immunoprecipitation and
proximity ligation assays. The results supported the fact that the
interaction between LDLR and PCSK9 is independent of CAP1
(Supplementary material online, Figure S5).
We generated a CAP1 knock-out mouse by TALEN-mediated tar-
geting of CAP1 exon 3 that allowed us to determine the role of
CAP1 in vivo (Supplementary material online, Figure S6).
Heterozygous knock-out mice (CAP1þ/- mouse) were used, as the
CAP1 homozygous knock-out mice died at embryonic day 16.5
(Supplementary material online, Figure S7). The organs of CAP1þ/-
mice did not differ from the wild-type organs up to approximately
16 weeks (Supplementary material online, Figure S8), and the mRNA
and protein levels of CAP1 were significantly decreased in various
organs from the CAP1þ/- mouse (Supplementary material online,
Figure S9). Thus, we compared the expression levels of LDLR and
PCSK9 in the liver of CAP1þ/- mice and CAP1þ/þ mice with or with-
out a high-fat diet. While there was no significant difference in LDLR
mRNA expression via real-time PCR (Supplementary material online,
Figure S10), the protein levels of LDLR were significantly higher in the
CAP1þ/- mice than in the CAP1þ/þ mice (Figure 3C). Accordingly,
under high-fat diet, the CAP1þ/- mice had lower total cholesterol and
LDL-C levels than WT mice (Figure 3D). There was no significant dif-
ference in the plasma triglyceride (TG) and high-density lipoprotein
cholesterol (HDL-C) levels. Then, we fractionated the plasma lipo-
proteins by fast-performance liquid chromatography, which con-
firmed the decrease in the LDL-C and VLDL-C levels and the shift of
HDL-C towards the large-buoyant form in the CAP1þ/- mice com-
pared to the CAP1þ/þ mice fed a high-fat diet (Figure 3E). We over-
expressed PCSK9 using adeno-associated virus both in CAP1þ/- and
CAP1þ/þ mice and measured the levels of LDLR expression and
LDL-C (Figure 3F–H). In CAP1 hetero-knock-out mice, a decrease or
degradation of LDLR protein by transduction of PCSK9 was
prevented, leading to improved cholesterol profiles compared to
wild type animals.
CAP1 guides the PCSK9/LDLR complex
to undergo caveolae-dependent endo-
cytosis, leading to degradation of LDLR
The PCSK9-mediated degradation of LDLR was exclusively blocked
by the lysosomal protease inhibitor (E-64d), but not by inhibitors of
the proteasome (lactacystin) or autophagy (bafilomycin), suggesting
that LDLRs are degraded by the lysosomal pathway as previously
reported13,14 (Supplementary material online, Figure S11). This finding
was also illustrated in HepG2 cells treated with PCSK9 conjugated
with Cy3 dye (PCSK9-Cy3) by tracking LDLRs with PCSK9-Cy3, the
endosomal marker EEA1 (early endosome antigen 1), and the lyso-
somal marker LAMP2 (lysosome-associated membrane protein 2) at
various time points (Supplementary material online, Figure S12A).
After the PCSK9-Cy3 treatment, EEA1 was colocalized with PCSK9
and LDLR within 30 min (Supplementary material online, Figure S12B
and C). Then, LAMP2 appeared, colocalizing with PCSK9 and LDLR
within 60 min. It increased until 240 min, at which point PCSK9 and
LDLR disappeared (Supplementary material online, Figure S12A, C).
This lysosome formation, but not the early endosome formation, was
blocked by CAP1 depletion (Figure 4A, Supplementary material on-
line, Figure S13).
In the raft isolation experiment, endogenous PCSK9 before ex-
ogenous application was localized more in non-raft fractions [raft
(36.8%)/non-raft (63.2%)]. Within 30 min after application of exogen-
ous PCSK9, it was mainly incorporated in lipid raft fractions [raft
(54.3%)/non-raft (45.7%)] (Figure 4B and C), which are closely
involved in caveolae formation. LDLR expression in the membrane
fraction decreases 60 min after the PCSK9 treatment. However, in
the CAP1-deficient cells, there is no significant change in the PCSK9
and LDLR expression patterns, even after PCSK9 treatment (Figure
4B and C). It is reported that early endosome formation by PCSK9 is
mediated by the clathrin pathway.14,15 However, PCSK9 treatment
increased the numbers of endosomes colocalized with not only cla-
thrin but also caveolin (Supplementary material online, Figure S14).
Interestingly, regarding the enhanced endosome formation, either
with clathrin or caveolin, after PCSK9 treatment, CAP1 knock-down
decreased only the caveolin-endosome but not the clathrin-
endosome, suggesting that CAP1 induces caveolin-mediated endo-
cytosis of the PCSK9/LDLR complex but not clathrin-mediated
endocytosis (Figure 4D and E).
Therefore, we knocked down caveolin or clathrin to compare cav-
eolin- and clathrin-mediated LDLR endocytosis, respectively, follow-
ing treatment with PCSK9. In the caveolin-deficient cells, the LDLR
was not degraded even with PCSK9 treatment (Figure 4F). In the
clathrin-deficient cells, however, the PCSK9 treatment was able to
degrade the LDLR in a dose-dependent manner, implying that
PCSK9-mediated LDLR degradation is clathrin-independent (Figure
4G). In the absence of caveolin, LAMP2 could not form and LDLR
was not degraded by PCSK9, whereas in the absence of clathrin,
LAMP2 appeared and LDLR was degraded (Figure 4H). In addition,
the knock-down of CAP1 was unable to produce LAMP2, suggesting
that CAP1 is closely involved in the caveolin-mediated degradation of
LDLR by PCSK9 (Figure 4H). Next, we evaluated the effect of CAP1
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Figure 3 CAP1 is required for PCSK9-induced LDLR degradation. (A) LDLR degradation induced by PCSK9 was attenuated by CAP1 siRNA
(upper panel). The representative figure of three independent experiments. Quantification of the expression levels of LDLR (bottom panel). (B)
PCSK9-induced LDLR degradation was rescued by wild-type CAP1 and the ~ACBD mutant (upper panel). Quantification of the expression levels
of LDLR (bottom panel). (C) The protein expression levels of LDLR were significantly greater in the CAP1þ/- mice than those in the CAP1þ/þ mice,
regardless of the diet. Pro-PCSK9 (P) and mature PCSK9 (M) are indicated with bold line. Quantification of the expression levels of LDLR/GAPDH in
CAP1þ/- vs. CAP1þ/þ mice (bottom panel). (D) Enzymatic measurement of the plasma cholesterol levels in CAP1þ/- and CAP1þ/þ mice fed either
high fat- or chow diet for 16 weeks (n = 6 per group).
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Figure 3 Continued.
(E) Cholesterol levels in FPLC fractions from pooled plasma samples (n = 5 per group) in CAPþ/- (red) and CAP1þ/þ (blue) mice fed high-fat diet.
(F–H) Overexpression of PCSK9 in both CAP1þ/- and CAP1þ/þmice using adeno-associated virus. (F) Immunoblot analysis of PCSK9-induced LDLR
degradation in CAP1þ/- and CAP1þ/þ mice liver. Pro-PCSK9 (P) and mature PCSK9 (M) are indicated with bold line. The representative figure of
three independent experiments. Quantification of the expression levels of LDLR (bottom left), PCSK9 (bottom middle), and CAP1 (bottom right) (n
= 9). (G) Plasma levels of hPCSK9 were measured by ELISA (n = 5 per group). (H) Enzymatic analysis of plasma cholesterol levels in CAP1þ/- and
CAP1þ/þmice with or without PCSK9 overexpression (n = 5 per group).
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Figure 4 CAP1 mediates the caveolin-dependent endocytosis and lysosomal degradation of LDLR. (A) Immunofluorescent staining of HepG2 cells
with LDLR (green), PCSK9 (red), and the lysosomal marker LAMP2 (white) 240 min after treatment with recombinant hPCSK9. (B) Membrane frac-
tionation and immunoblot analysis demonstrating the cellular distribution of LDLR, PCSK9 and CAP1 after PCSK9 treatment in HepG2 cells treated
with either a control or CAP1 siRNA. The representative figure of three independent experiments. (C) Quantification of the immunoblot. (D and E)
Co-localization of endosomal marker EEA1 with clathrin.
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Figure 4 Continued.
(D) and caveolin-1 (E) in HepG2 cells treated with recombinant rhPCSK9 for 30 min. Overlap coefficients: mean ± standard deviation. (F and G)
Immunoblot analysis of LDLR expression demonstrating that PCSK9-induced LDLR degradation was attenuated by caveolin siRNA (F) in HepG2
cells but was not affected by clathrin siRNA (G). Quantification of the expression levels of LDLR (bottom panel, n = 3). (H) Immunofluorescent stain-
ing of HepG2 cells with LDLR (green) and the lysosomal marker LAMP2 (red) 240 min after hPCSK9 treatment. HepG2 cells were pre-treated with
either the control, CAP1, caveolin1, or clathrin siRNA.
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Figure 4 Continued.
(I) Immunofluorescent staining of HepG2 cells with EGF (red) and albumin (green). Bar indicates 10 lm. The representative figure of three independ-
ent experiments, and the dots in a cell were counted from ten random fields of each independent experiment (bottom panel). (J) LDLR degradation
by the overexpression of PCSK9 was attenuated by CAP1 siRNA and caveolin1 siRNA but not clathrin siRNA. Bar graphs showing the LDLR and
PCSK9 level in the lysate. The representative figure of three independent experiments.
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Figure 4 Continued.
(K) Transmission electron microscopic images of HepG2 cells without treatment (upper left) or with pretreatment with either a control siRNA
(lower left) or CAP1 siRNA (lower right) and exposed to PCSK9 for 15 min. Numerous caveolae (yellow circle), caveolin-vesicles (yellow arrows),
and clathrin-coated vesicles (red arrows) are observed in the control siRNA-PCSK9-treated cells, while only clathrin-coated vesicles are observed in
the CAP1 siRNA-PCSK9-treated cells. Bar indicates 0.5 lm; ER, endoplasmic reticulum; MT, mitochondrion; N, nucleus. (L) hPCSK9-Flag and either
wild-type CAP1-Myc or its mutants were overexpressed in HEK 293 cells. Immunoprecipitation with anti-Flag beads and immunoblotting with Myc
or caveolin-1. (M) LDLR localizes to the recycling endosomes in PCSK9-deficient cells but not much in clathrin-deficient cells. Immunofluorescent
staining of HepG2 cells ‘at 4 h after LDL-C treatment’ with Rab11 (red), LDLR (green), and DAPI (blue). Colocalization of Rab11 and LDLR was
measured and expressed as percent colocalization (bottom graph). (N) Schematic model in which LDLR undergoes caveolae-dependent endocytosis
and lysosomal degradation induced by PCSK9. CAP1 mediates this process by interfacing PCSK9 with caveolin through the SH3BD and ACBD.

































..deficiency on the endocytosis of EGF or albumin. EGF and its recep-
tor complex is mainly internalized by clathrin-dependent
endocytosis,16 whereas albumin uptake has been reported to be de-
pendent on caveolae.17 The caveolin-dependent albumin endocytosis
was significantly decreased by CAP1 deficiency, whereas the clathrin-
dependent EGF receptor endocytosis was not affected (Figure 4I).
These observations suggest that CAP1 might be involved not only in
the endocytosis of the PCSK9/LDLR complex but also in caveolin-
dependent endocytosis in general. LDLR degradation mediated by
endogenously overexpressed PCSK9 was similarly attenuated by
siRNA against CAP1 or caveolin (Figure 4J). An electron microscopic
analysis (Figure 4K) demonstrated that only caveosome formation,
but not clathrin, after PCSK9 treatment was significantly attenuated
by CAP1 siRNA. The mechanism by which CAP1 guides the PCSK9/
LDLR complex to the caveosome is based on the binding of the AC-
domain of CAP1 to caveolin-1. In the immunoprecipitation experi-
ment, PCSK9 (with LDLR) can form a complex with wtCAP1 and
caveolin-1, whereas it cannot in the presence of mutant CAP1, such
as ~SH3BD~actinBD or ~ACBD mutant CAP1 (Figure 4L), sug-
gesting again that the SH3BD of CAP1 is necessary for binding with
the CRD of PCSK9. The ACBD of CAP1 is necessary for binding
with caveolin. Immunoprecipitation assay with wild-type mouse liver
lysate also showed that caveolin binds to LDLR, CAP1, and PCSK9
(Supplementary material online, Figure S15). In addition, LDLR/
PCSK9/CAP1 complexes co-localized with caveolin in mouse liver
(Supplementary material online, Figure S16). LDLR endocytosis co-
stained with early endosomal marker Rab5,18 1 h after LDL-C treat-
ment significantly decreased by both the clathrin siRNA and caveolin
siRNA. When we blocked PCSK9 with the siRNA-attenuating LDLR
degradation pathway, caveolin-mediated LDLR endocytosis was sig-
nificantly reduced, whereas there was no significant change in
clathrin-mediated endocytosis (Supplementary material online, Figure
S17). Furthermore, when we co-stained LDLR with Rab11, which is
related to the recycling mechanism,18 4 h after LDL-C treatment, the
amount of recycling LDLR was significantly decreased by clathrin
siRNA relative to that with caveolin siRNA (Figure 4M).
Discussion
Previous milestone discoveries in human genetics have established a
clear link between PCSK9 function and LDL-C concentrations.19 The
gain-of-function missense mutations in PCSK9 cause a rare form of
autosomal codominant familial hypercholesterolaemia.20 Conversely,
Take home figure CAP1 is a new binding partner of PCSK9 and mediates caveolae-dependent endocytosis and lysosomal degradation of
LDLR.






















































































..loss-of-function mutations in PCSK9 have been associated with hypo-
cholesterolaemia and protection against atherosclerotic cardiovascu-
lar diseases.21 Mechanistic analysis revealed that secreted PCSK9
binds to the LDLR at the hepatocyte cell surface and promotes its
endocytosis and lysosomal degradation.10 Molecular mapping of the
PCSK9-LDLR binding interface led to the development of therapeut-
ic anti-PCSK9 monoclonal antibodies.22 We have further explored in
more detail how PCSK9 directed LDLR towards endocytosis and
lysosomal degradation after binding to LDLR. In the present study,
we have broadened our understanding of the process by identifying
CAP1 as a new binding partner for PCSK9. First, we showed that the
SH3BD of CAP1 binds directly with the CRD of PCSK9. Two loss-of-
function polymorphisms found in human PCSK9 had a defective
interaction with CAP1. We could prevent PCSK9-mediated LDLR
degradation not only in cultured liver cells with siRNA against CAP1
but also in heterozygous CAP1 knock-out mice, which had lower
plasma LDL-C levels. Finally, our mechanistic study elucidated that
CAP1 binds to caveolin-1, subsequently leading the PCSK9-LDLR
complex to caveolae-dependent endocytosis and lysosomal
degradation.
Internalization of LDLR has been postulated as clathrin-mediated
endocytosis. The adaptor protein ARH binds to the FXNPXY motif
of the LDLR as well as clathrin and AP-2, which forms clathrin coated
pits and leads to the intracellular recycling pathway.23 siRNA against
clathrin inhibited LDLR degradation by PCSK9 overexpression in
HepG2 cells.14 However, the recycling pathway and endogenously
overexpressed PCSK9 might not be related to the endocytosis pro-
cess that physiologically occurs for the degradation of LDLR. PCSK9-
mediated degradation of LDLR could occur under hypertonic condi-
tions, which blocks clathrin-coated pit formation.15 We observed
that PCSK9-mediated LDLRs endocytosis occurred both via
clathrin- and caveolae-dependent pathways. However, in the
caveolin-deficient cells, the LDLR was not degraded with the PCSK9
treatment (Figure 4F), while LDLR in the clathrin-deficient cells were
degraded in a dose-dependent manner (Figure 4G). The fate of the
LDLR/PCSK9 complex differed depending on the endosome path-
way: degradation in the caveolin-pathway vs. recycling in the
clathrin-mediated pathway. There is a similar example of cell surface
receptors that have two different fates, degradation vs. recycling, de-
pending on the binding partners. TGFbRs present in lipid rafts are
integrated into ‘caveolin-1 positive vesicles’, preferentially delivered
to the SMAD7-SMURF2-ubiquitin-ligase complex, and degraded.24
However, for TGFb-induced SMAD2 activation, TGFbRs are inter-
nalized through ‘clathrin-mediated endocytosis’ and found in Rab11-
positive ‘recycling endosomes’, not in p62-positive late endosomes.25
As summarized in Figure 4N, LDLR enters cells once bound to
LDL-C via clathrin-dependent endocytosis, and then the acidic pH of
endosomes causes the allosteric dissociation of the LDLR and its
recycling to the cell surface.26 During the process, adaptor molecules,
such as ARH and DAB2, mediate clathrin-dependent
endocytosis.27,28 While PCSK9 also promotes clathrin-dependent
endocytosis, it does not lead to lysosomal degradation of LDLR
(Figure 4G and H). When the complex of LDLR and PCSK9 interacts
with CAP1, however, these proteins enter cells by caveolin-
dependent endocytosis because CAP1 can bind to caveolin-1
through the ACBD (Figure 4L). Then, caveolin-coated endosomes
containing LDLR/PCSK9/CAP1 are escorted to lysosomes for deg-
radation. The identification of CAP1 as the unknown binding partner
of PCSK9 during LDLR degradation clearly delineates caveolin-
dependent LDLR endocytosis and lysosomal degradation.
Supplementary material
Supplementary material is available at European Heart Journal online.
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